Dose-escalated radiation does not benefit patients with low-risk prostate cancer
the ONA take:
According to a new study published online ahead of print this week in JAMA Oncology, researchers have found that higher radiation dose is associated with improved survival rates among men with medium- and high-risk prostate cancer. However, this association was not observed in patients with low-risk disease.
For the study, researchers analyzed data from 42,481 men with prostate cancer included in the National Cancer Database. Of those, 12,229 had low-risk disease, 16,714 had intermediate-risk disease, and 13,538 had high-risk prostate cancer. Patients were all diagnosed between 2004 and 2006 and received either standard-dose external-beam radiation therapy or dose-escalated radiation.
Results showed that higher dose radiotherapy was associated with increased survival in those with intermediate- and high-risk disease, but not in those with low-risk disease. The findings suggest that aggressive radiotherapy may not be beneficial in men with low-risk prostate cancer, adding to the evidence that watchful waiting or active surveillance may be better for these patients.
Higher radiation dose is associated with improved survival rates among men with medium- and high-risk prostate cancer.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Nasal Biomarker in Smokers Could Predict Lung Cancer
- Arm Lymphoscintigraphy After Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy in Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|